Krystal Biotech (NASDAQ:KRYS – Get Free Report) and MeiraGTx (NASDAQ:MGTX – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.
Analyst Ratings
This is a summary of current recommendations for Krystal Biotech and MeiraGTx, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Krystal Biotech | 0 | 1 | 9 | 0 | 2.90 |
| MeiraGTx | 0 | 0 | 2 | 0 | 3.00 |
Krystal Biotech currently has a consensus target price of $187.89, suggesting a potential downside of 5.44%. MeiraGTx has a consensus target price of $22.50, suggesting a potential upside of 422.04%. Given MeiraGTx’s stronger consensus rating and higher possible upside, analysts plainly believe MeiraGTx is more favorable than Krystal Biotech.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Krystal Biotech | $166.23 million | 34.13 | $10.93 million | $1.87 | 106.25 |
| MeiraGTx | $8.12 million | 34.12 | -$84.03 million | ($1.17) | -3.68 |
Krystal Biotech has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Krystal Biotech and MeiraGTx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Krystal Biotech | N/A | -5.74% | -5.45% |
| MeiraGTx | -651.19% | -122.82% | -48.11% |
Risk and Volatility
Krystal Biotech has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.
Insider and Institutional Ownership
86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 14.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 8.4% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Krystal Biotech beats MeiraGTx on 11 of the 14 factors compared between the two stocks.
About Krystal Biotech
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
About MeiraGTx
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
